ArticleScientific reports2025
Occurrence, distribution, and risk assessment of selected pharmaceuticals in municipal biosolids from the four wastewater treatment plants in Gauteng Province, South Africa.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The presence of pharmaceutical residues in municipal biosolids is an emerging environmental concern due to their potential accumulation in agricultural soils following land application. While parent compounds like sulfamethoxazole and carbamazepine are frequently studied, data on their transformation products in biosolids remain limited. This study assessed the occurrence, distribution, and environmental risks of sulfamethoxazole, carbamazepine, and two of their selected metabolites in biosolids collected from four wastewater treatment plants (WWTPs) in Gauteng Province, South Africa. A single biosolid sampling campaign was conducted across the four WWTPs, each characterized by varying operational parameters. Sulfamethoxazole and its two metabolites were not detected in any of the samples. In contrast, carbamazepine and its metabolites-carbamazepine-10,11-epoxide and carbamazepine diol-were detected, with maximum concentrations of 150.67, 601.95, and 89.18 ng/g dry weight, respectively. Carbamazepine and carbamazepine-10,11-epoxide occurred in all samples, while carbamazepine diol appeared in 50% of the samples. The concentration patterns varied across WWTPs and were significantly correlated with biosolid pH, organic carbon content, and oxidation-reduction potential. Risk quotient analysis indicated that the predicted soil concentrations of carbamazepine (0.50 ng/g dry weight) pose negligible ecological risk (RQ = 0.003). However, due to a lack of ecotoxicological data, environmental risks associated with carbamazepine-10,11-epoxide and carbamazepine diol could not be fully assessed. Overall, the findings highlight the persistence of carbamazepine and its metabolites in biosolids and underscore the importance of optimizing sludge treatment processes and generating toxicity data for pharmaceutical metabolites to support safe land application practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.